Abstract
We developed this rufinamide guideline using drug prescribing information and reviewing the available literature on relevant neuropsychiatric disorders in populations without intellectual disabilities because of the dearth of available literature on the population with intellectual disabilities. This guideline includes indications; contraindications; assessments prior to and during treatment; dosing with particular focus on dosing modifications required by drug–drug interactions, personal characteristics; and adverse drug reactions. The procedures contained in this guideline may not fully account for all of the possible risks of treatment in this population because of the limited studies available; thus, there will be a need to periodically update this guideline as new information becomes available. Nevertheless, we believe that this guideline provides a useful resource for clinicians who treat epilepsy in adult individuals with intellectual disabilities. A rufinamide drug utilization review that summarizes this guideline is described.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aldenkamp, A. P., & Alpherts, W. C. (2006). The effect of the new antiepileptic drug rufinamide on cognitive functions. Epilepsia, 47, 1153–1159.
Arana, A., Wentworth, C. E., Ayuso-Mateos, J. L., & Arellano, F. M. (2010). Suicide-related events in patients treated with antiepileptic drugs. The New England Journal of Medicine, 363, 542–551.
Arroyo, S. (2007). Rufinamide. Neurotherapeutics, 4, 155–162.
Bell, G. S., Mula, M., & Sander, J. W. (2009). Suicidality in people taking antiepileptic drugs: What is the evidence? CNS Drugs, 23, 281–292.
Biton, V., Krauss, G., Vasquez-Santana, B., Bibbiani, F., Mann, A., Perdomo, C., et al. (2011). A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. Epilepsia, 52, 234–242.
Brodie, M. J., Rosenfeld, W. E., Vazquez, B., Sachdeo, R., Perdomo, C., Mann, A., et al. (2009). Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: A randomized placebo-controlled trial. Epilepsia, 50, 1899–1909.
Cardot, J. M., Lecaillon, J. B., Czendlik, C., & Godbillon, J. (1998). The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers. Biopharmaceutics & Drug Disposition, 19, 259–262.
Cheng-Hakimian, A., Anderson, G. D., & Miller, J. W. (2006). Rufinamide: Pharmacology, clinical trials, and role in clinical practice. International Journal of Clinical Practice, 60, 1497–1501.
de Leon, J., Armstrong, S. C., & Cozza, K. L. (2005). The dosing of atypical antipsychotics. Psychosomatics, 46, 262–273.
Deeks, E. D., & Scott, L. J. (2006). Rufinamide. CNS Drugs, 20, 751–760.
Eisai Inc. (2011). Benzel (rufinamide) 200, 400 mg tablets, 40 mg/ml oral suspension (highlights of prescribing information). Woodcliff Lake, NJ: Eiasai Inc.
Elger, C. E., Stefan, H., Mann, A., Narurkar, M., Sun, Y., & Perdomo, C. (2010). A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Research, 88, 255–263.
Fava, M. (2010). The possible antianxiety and mood-stabilizing effects of rufinamide. Psychotherapy and Psychosomatics, 79, 194–195.
Glauser, T., Kluger, G., Sachdeo, R., Krauss, G., Perdomo, C., & Arroyo, S. (2008). Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology, 70, 1950–1958.
Hakimian, S., Cheng-Hakimian, A., Anderson, G. D., & Miller, J. W. (2007). Rufinamide: A new anti-epileptic medication. Expert Opinion on Pharmacotherapy, 8, 1931–1940.
Harris, E. C., & Barraclough, B. (1997). Suicide as an outcome for mental disorders. A meta-analysis. The British Journal of Psychiatry, 170, 205–228.
Herman, S. T. (2009). Adopting an orphan drug: Rufinamide for Lennox-Gastaut syndrome. Epilepsy Current, 9, 72–74.
Hesdorffer, D. C., Berg, A. T., & Kanner, A. M. (2010). An update on antiepileptic drugs and suicide: Are there definitive answers yet? Epilepsy Current, 10, 137–145.
Karolchyk, M. A., & Schmidt, D. (2002). Drugs in development. Rufinamide. In R. H. Levy, R. H. Mattson, B. S. Meldrum, & E. Perucca (Eds.), Antiepileptic drugs (5th ed., pp. 906–912). Philadelphia, PA: Lippincott Williams & Wilkins.
Kaufman, K. R., & Struck, P. J. (2011). Activation of suicidal ideation with adjunctive rufinamide in bipolar disorder. Epilepsy & Behavior, 20, 386–369.
Kluger, G., Kurlemann, G., Haberlandt, E., Ernst, J. P., Runge, U., Schneider, F., et al. (2009). Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: First European experience. Epilepsy & Behavior, 14, 491–495.
Kuehn, B. M. (2008). FDA warns of adverse events linked to smoking cessation drug and antiepileptics. The Journal of the American Medical Association, 299, 1121–1122.
May, T. W., Boor, R., Rambeck, B., Jürgens, U., Korn-Merker, E., & Brandt, C. (2011). Serum concentrations of rufinamide in children and adults with epilepsy: The influence of dose, age, and comedication. Therapeutic Drug Monitoring, 33, 214–221.
Merrick, J., Merrick, E., Lunsky, Y., & Kandel, I. (2006). A review of suicidality in persons with intellectual disability. The Israel Journal of Psychiatry and Related Science, 43, 258–264.
Perucca, E., Cloyd, J., Critchley, D., & Fuseau, E. (2008). Rufinamide: Clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia, 49, 1123–1141.
Saneto, R. P., & Anderson, G. D. (2009). Onset of action and seizure control in Lennox-Gaustaut syndrome: Focus on rufinamide. Therapeutics and Clinical Risk Management, 5, 271–280.
Shields, W. D. (2008). Children get their due: A study of pediatric epilepsy patients before drug approval. Neurology, 70, 1946–1947.
Stafstrom, C. E. (2009). Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide. Neuropsychiatric Disease and Treatment, 5, 547–551.
US Department of Mental Health and Human Services. (2008). Statistical review and evaluation: Antiepileptic drugs and suicidality. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf. Accessed 5.04.2011.
Wheless, J. W., & Vazquez, B. (2010). Rufinamide: A novel broad-spectrum antiepileptic drug. Epilepsy Current, 10, 1–6.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Appendix Drug Utilization Review: Rufinamide
Appendix Drug Utilization Review: Rufinamide
DRUG UTILIZATION REVIEW CRITERIA | CRITERIA MET | |||||
---|---|---|---|---|---|---|
RUFINAMIDE FOR ADULTS WITH IDs | YES | NO | NA | |||
1) Indication: Check one of the following indications for use. | ||||||
| For adjunctive treatment of seizures associated with Lennox–Gastaut syndrome. | |||||
| Off-label uses: adjunctive treatment of refractory partial seizures. Specify_________________________. When rufinamide is used for off-label indications, the chart will specifically include an explanatory note (Y___ N___). | |||||
To meet indication criteria this indication is present and documented. | | | ||||
2) Dose: Specify current formulation and dosages______________________. | ||||||
Rufinamide is administered with food. | | | | |||
Rufinamide is given two times/day (Y__ N__) unless otherwise recommended by a consultant with expertise in the area (Y__). | | | | |||
The first anticonvulsive daily dose was ≤ 400–800 mg/day (Y__ N__) unless otherwise recommended by a consultant with expertise in the area (Y__). | | | | |||
Dosages were increased ≤ 400–800 mg/day every 2 days (Y__ N__) unless otherwise recommended by a consultant with expertise in the area (Y__). | | | | |||
The maximum antiepileptic dose was ≤ 3,200 mg/day (Y__ N__) unless otherwise recommended by a consultant with expertise in the area (Y__). | | | | |||
Taking phenytoin__, carbamazepine__, phenobarbital__, primidone__. The chart documents the interaction (Y___ N___). The dosage of rufinamide may need to be increased when any of these antiepileptic drugs are added and the discontinuation of any of these inducers may need to be followed by a decrease in rufinamide dosage. | | | | |||
Taking valproate__. The chart documents the interaction (Y___ N___). The dosage of rufinamide may need to be decreased when valproate is added and the discontinuation of valproate may need to be followed by a decrease in rufinamide dosage. | | | | |||
Taking oral contraceptives___. The chart documents that the oral contraceptive may not be effective (Y___ N___). | | | | |||
Hemodialysis____. The chart documents that rufinamide doses are adjusted (Y___ N___). | | | | |||
To meet dose criteria all are Yes or NA. | | | ||||
3) Relative contraindications: Check left boxes of any present. | ||||||
| Pregnancy (Category C) or breastfeeding. | |||||
| Severe liver impairment. | |||||
Answer Yes if none is checked, or if any of the above are checked and rationale is documented in the chart to meet relative contraindication criteria. Answer No if rationale is NOT documented in the chart. | | | ||||
4) Baseline monitoring studies: | ||||||
| EKG. | |||||
| Liver function tests. | |||||
| Serum concentrations of the concomitantly administered antiepileptics that are usually followed by therapeutic drug monitoring. | |||||
Answer Yes (all completed) or No. If information is not available check NA. | | | | |||
5) Discontinuation: | ||||||
| Rufinamide is or was withdrawn slowly to minimize the potential of increased seizure frequency (Y___ N___). Abrupt withdrawal was justified by a major medical reason (Y___ N___). | | | | ||
6) Adverse drug reactions (ADRs) due to rufinamide: Check left boxes to indicate which ADRs are present. | ||||||
6.1) Common ADRs: | ||||||
| Somnolence or fatigue. | | Coordination abnormalities, dizziness, gait disturbances or ataxia. | |||
| Headaches. | | Nausea. | |||
| Convulsions. | |||||
6.2) Relatively uncommon ADRs: | ||||||
| QT shortening. | | Elevation in liver enzymes. | |||
| Other_____________ | | Other_____________ | |||
6.3) Potentially lethal ADRs: | ||||||
| Suicidal ideation or behavior. | |||||
Answer Yes (intervention or benefit/risk discussion after ADRs developed) or No (neither intervention nor benefit/risk discussion after ADRs developed) or NA (no abnormality developed). | | | |
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
de Leon, J. (2012). A Practitioner’s Guide to Prescribing Rufinamide for Adults with Intellectual Disabilities. In: de Leon, J. (eds) A Practitioner's Guide to Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-2012-5_18
Download citation
DOI: https://doi.org/10.1007/978-1-4614-2012-5_18
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-2011-8
Online ISBN: 978-1-4614-2012-5
eBook Packages: MedicineMedicine (R0)